Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple-stage screening and mortality in the Multiple Risk Factor Intervention Trial.

Lynn E Eberly1, James D Neaton, Avis J Thomas

  • 1Division of Biostatistics, School of Public Health, University of Minnesota, 420 Delaware Street SE, MMC 303, Minneapolis, MN 55455-0378, USA. lynn@biostat.umn.edu

Clinical Trials (London, England)
|November 12, 2005
PubMed
Summary

Clinical trial participants had lower mortality than non-volunteers and exclusions. Factors like medical screening and secular trends influence event rates and trial power, impacting long-term outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurochemical Endpoints to Inform Early-Stage Trials of Spinocerebellar Ataxia 2 and 3 in a Multisite Setting.

Annals of clinical and translational neurology·2026
Same author

Racial and Ethnic Disparities in the Time to Dual Incontinence and its Treatment in Older Adults after Nursing Home Admission.

Annals of gerontology and geriatric research·2026
Same author

Factors associated with severe neurological sequelae of COVID-19: findings from the multicenter COVID-BRAIN imaging cohort.

Frontiers in human neuroscience·2026
Same author

Disrupted neurovascular-endocrine coupling in type 1 diabetes with impaired awareness of hypoglycemia.

The Journal of clinical investigation·2026
Same author

Examination of oxidative stress and glutamate as potential mechanisms of N-acetylcysteine in the treatment of non-suicidal self-injury in young people assigned female at birth: randomised trial.

BJPsych open·2025
Same author

Reduced removal of waste products from energy metabolism takes center stage in human brain aging.

Scientific reports·2025

Area of Science:

  • Epidemiology
  • Clinical Trial Design
  • Biostatistics

Background:

  • Clinical trial design must account for factors influencing event rates, including medical screening, the 'healthy volunteer' effect, run-in phases, and secular trends.
  • The Multiple Risk Factor Intervention Trial (MRFIT) observed lower coronary heart disease (CHD) mortality than projected, prompting an investigation into contributing factors.

Purpose of the Study:

  • To explore factors contributing to observed mortality differences in the MRFIT trial compared to projections.
  • To determine if these mortality differences persisted throughout the 25-year follow-up period.

Main Methods:

  • Proportional hazards models were employed to compare 25-year mortality.
  • Analyses stratified participants by trial eligibility, self-exclusions, medical exclusions, and participation status.

Related Experiment Videos

Main Results:

  • Men excluded for medical reasons exhibited higher total and CHD mortality compared to those not excluded, persisting over 25 years.
  • Trial volunteers demonstrated lower total and CHD mortality than those who discontinued participation.
  • Exclusions due to adherence concerns showed higher total and non-cardiovascular disease (CVD) mortality, but not significantly higher CVD or CHD mortality.

Conclusions:

  • 25-year mortality was significantly elevated for non-volunteers and excluded individuals.
  • Observed vs. predicted mortality differences were largely due to volunteers and exclusions, with secular trends also impacting CHD mortality.
  • Anticipating these factors in trial design is crucial, even for shorter trials, to ensure accurate power calculations and outcome projections.